The Singapore National Precision Medicine Strategy.

Humans Singapore Precision Medicine / methods Delivery of Health Care Asia

Journal

Nature genetics

ISSN: 1546-1718

Titre abrégé: Nat Genet

Pays: United States

ID NLM: 9216904

Informations de publication

Date de publication:
02 2023

Historique:

received: 30 03 2022

accepted: 30 11 2022

pubmed: 20 1 2023

medline: 16 2 2023

entrez: 19 1 2023

Statut: ppublish

Résumé

Precision medicine promises to transform healthcare for groups and individuals through early disease detection, refining diagnoses and tailoring treatments. Analysis of large-scale genomic-phenotypic databases is a critical enabler of precision medicine. Although Asia is home to 60% of the world's population, many Asian ancestries are under-represented in existing databases, leading to missed opportunities for new discoveries, particularly for diseases most relevant for these populations. The Singapore National Precision Medicine initiative is a whole-of-government 10-year initiative aiming to generate precision medicine data of up to one million individuals, integrating genomic, lifestyle, health, social and environmental data. Beyond technologies, routine adoption of precision medicine in clinical practice requires social, ethical, legal and regulatory barriers to be addressed. Identifying driver use cases in which precision medicine results in standardized changes to clinical workflows or improvements in population health, coupled with health economic analysis to demonstrate value-based healthcare, is a vital prerequisite for responsible health system adoption.

Identifiants

DOI: 10.1038/s41588-022-01274-x PMID: 36658435

pubmed: 36658435

doi: 10.1038/s41588-022-01274-x

pii: 10.1038/s41588-022-01274-x

doi:

Types de publication

Journal Article Review Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

Pagination

178-186

Investigateurs

Rob M Van Dam (RM)

Yik Ying Teo (YY)

Marie Loh (M)

Paul Eillot (P)

Eng Sing Lee (ES)

Joanne Ngeow (J)

Elio Riboli (E)

Rinkoo Dalan (R)

Irfahan Kassam (I)

Lakshmi Narayanan Lakshmanan (LN)

Tock Han Lim (TH)

Hong Kiat Ng (HK)

Theresia Mina (T)

Darwin Tay (D)

Charumathi Sabanayagam (C)

Yih Chung Tham (YC)

Tyler Rim (T)

Tin Aung (T)

Miao Ling Chee (ML)

Hengtong Li (H)

Miao Li Chee (ML)

Khung Keong Yeo (KK)

Stuart Alexander Cook (SA)

Chee Jian Pua (CJ)

Chengxi Yang (C)

Yap Seng Chong (YS)

Johan Gunnar Eriksson (JG)

Kok Hian Tan (KH)

Fabian Yap (F)

Chia Wei Lim (CW)

Pi Kuang Tsai (PK)

Wen Jie Chew (WJ)

Wey Ching Sim (WC)

Li-Xian Grace Toh (LG)

Clarabelle Bitong Lin (CB)

Yee Yen Sia (YY)

Tat Hung Koh (TH)

Wee Yang Meah (WY)

Joanna Hui Juan Tan (JHJ)

Justin Jeyakani (J)

Jack Ow (J)

Shimin Ang (S)

Ashar J Malik (AJ)

Dimitar Kenanov (D)

Informations de copyright

Références

Shapiro, M. D., Tavori, H. & Fazio, S. PCSK9: from basic science discoveries to clinical trials. Circ. Res. 122, 1420–1438 (2018).

doi: 10.1161/CIRCRESAHA.118.311227 pubmed: 29748367 pmcid: 5976255

Sahin, U., Karikó, K. & Türeci, Ö. mRNA-based therapeutics—developing a new class of drugs. Nat. Rev. Drug Discov. 13, 759–780 (2014).

doi: 10.1038/nrd4278 pubmed: 25233993

Global Spending on Health: a World in Transition (WHO, 2019).

Global Health Estimates 2019: Life Expectancy, 2000–2019 (WHO, 2020).

Schroeder, S. A. Shattuck Lecture. We can do better—improving the health of the American people. N. Engl. J. Med. 357, 1221–1228 (2007).

doi: 10.1056/NEJMsa073350 pubmed: 17881753

Roden, D. M. et al. Pharmacogenomics. Lancet 394, 521–532 (2019).

doi: 10.1016/S0140-6736(19)31276-0 pubmed: 31395440 pmcid: 6707519

Le, D. T. et al. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 372, 2509–2520 (2015).

doi: 10.1056/NEJMoa1500596 pubmed: 26028255 pmcid: 4481136

Olstad, D. L. & McIntyre, L. Reconceptualising precision public health. BMJ Open 9, e030279 (2019).

doi: 10.1136/bmjopen-2019-030279 pubmed: 31519678 pmcid: 6747655

Middleton, P. G. et al. Elexacaftor–tezacaftor–ivacaftor for cystic fibrosis with a single Phe508del allele. N. Engl. J. Med. 381, 1809–1819 (2019).

doi: 10.1056/NEJMoa1908639 pubmed: 31697873 pmcid: 7282384

Cully, M. Target validation: genetic information adds supporting weight. Nat. Rev. Drug Discov. 14, 525 (2015).

doi: 10.1038/nrd4692 pubmed: 26228753

King, E. A., Davis, J. W. & Degner, J. F. Are drug targets with genetic support twice as likely to be approved? Revised estimates of the impact of genetic support for drug mechanisms on the probability of drug approval. PLoS Genet. 15, e1008489 (2019).

doi: 10.1371/journal.pgen.1008489 pubmed: 31830040 pmcid: 6907751

Ochoa D. et al. Human genetics evidence supports two-thirds of the 2021 FDA-approved drugs. Nat. Rev. Drug Discov. 21, 551 (2022).

Stark, Z. et al. Integrating genomics into healthcare: a global responsibility. Am. J. Hum. Genet. 104, 13–20 (2019).

doi: 10.1016/j.ajhg.2018.11.014 pubmed: 30609404 pmcid: 6323624

The All of Us Research Program Investigators et al. The ‘All of Us’ Research Program. N. Engl. J. Med. 381, 668–676 (2019).

Turnbull, C. et al. The 100 000 Genomes Project: bringing whole genome sequencing to the NHS. BMJ 361, k1687 (2018).

doi: 10.1136/bmj.k1687 pubmed: 29691228

Stark, Z. et al. Australian genomics: a federated model for integrating genomics into healthcare. Am. J. Hum. Genet. 105, 7–14 (2019).

doi: 10.1016/j.ajhg.2019.06.003 pubmed: 31271757 pmcid: 6612707

Cohn, E. G., Henderson, G. E. & Appelbaum, P. S. Distributive justice, diversity, and inclusion in precision medicine: what will success look like? Genet. Med. 19, 157–159 (2017).

Caffrey, M. Disparities in cancer care: has precision medicine widened the gap? AJMC (22 April 2021).

Sirugo, G., Williams, S. M. & Tishkoff, S. A. The missing diversity in human genetic studies. Cell 177, 26–31 (2019).

doi: 10.1016/j.cell.2019.02.048 pubmed: 30901543 pmcid: 7380073

Taliun, D. et al. Sequencing of 53,831 diverse genomes from the NHLBI TOPMed Program. Nature 590, 290–299 (2021).

doi: 10.1038/s41586-021-03205-y pubmed: 33568819 pmcid: 7875770

Karczewski, K. J. et al. The mutational constraint spectrum quantified from variation in 141,456 humans. Nature 581, 434–443 (2020).

doi: 10.1038/s41586-020-2308-7 pubmed: 32461654 pmcid: 7334197

Manrai, A. K. et al. Genetic misdiagnoses and the potential for health disparities. N. Engl. J. Med. 375, 655–665 (2016).

doi: 10.1056/NEJMsa1507092 pubmed: 27532831 pmcid: 5292722

Martin, A. R. et al. Clinical use of current polygenic risk scores may exacerbate health disparities. Nat. Genet. 51, 584–591 (2019).

doi: 10.1038/s41588-019-0379-x pubmed: 30926966 pmcid: 6563838

Martin, A. R. et al. Human demographic history impacts genetic risk prediction across diverse populations. Am. J. Hum. Genet. 100, 635–649 (2017).

doi: 10.1016/j.ajhg.2017.03.004 pubmed: 28366442 pmcid: 5384097

Privé, F. et al. Portability of 245 polygenic scores when derived from the UK Biobank and applied to 9 ancestry groups from the same cohort. Am. J. Hum. Genet. 109, 12–23 (2022).

doi: 10.1016/j.ajhg.2021.11.008 pubmed: 34995502 pmcid: 8764121

Graham, S. E. et al. The power of genetic diversity in genome-wide association studies of lipids. Nature 600, 675–679 (2021).

doi: 10.1038/s41586-021-04064-3 pubmed: 34887591 pmcid: 8730582

Atkinson, E. G. et al. Tractor uses local ancestry to enable the inclusion of admixed individuals in GWAS and to boost power. Nat. Genet. 53, 195–204 (2021).

doi: 10.1038/s41588-020-00766-y pubmed: 33462486 pmcid: 7867648

Mahajan, A. et al. Trans-ancestry genetic study of type 2 diabetes highlights the power of diverse populations for discovery and translation. Nat. Genet. 54, 560–572 (2022).

Chambers, J. C. et al. Epigenome-wide association of DNA methylation markers in peripheral blood from Indian Asians and Europeans with incident type 2 diabetes: a nested case–control study. Lancet Diabetes Endocrinol. 3, 526–534 (2015).

Chandalia, M. et al. Insulin resistance and body fat distribution in South Asian men compared to Caucasian men. PLoS ONE 2, e812 (2007).

doi: 10.1371/journal.pone.0000812 pubmed: 17726542 pmcid: 1950568

Wu, D. et al. Genetic admixture in the culturally unique Peranakan Chinese population in Southeast Asia. Mol. Biol. Evol. 38, 4463–4474 (2021).

doi: 10.1093/molbev/msab187 pubmed: 34152401 pmcid: 8476152

Population Trends, 2021 (Singapore Department of Statistics, 2021).

Government Health Expenditure and Healthcare Financing (Singapore Ministry of Health, 2018).

GBD 2017 Disease and Injury Incidence and Prevalence Collaborators Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 392, 1789–1858 (2018).

doi: 10.1016/S0140-6736(18)32279-7

Huang, K. K. et al. Genomic and epigenomic profiling of high-risk intestinal metaplasia reveals molecular determinants of progression to gastric cancer. Cancer Cell 33, 137–150 (2018).

doi: 10.1016/j.ccell.2017.11.018 pubmed: 29290541

Metspalu, A., Köhler, F., Laschinski, G., Ganten, D. & Roots, I. The Estonian Genome Project in the context of European genome research. Dtsch. Med. Wochenschr. 129, S25–S28 (2004).

pubmed: 15133739

Chen, J. et al. Genomic landscape of lung adenocarcinoma in East Asians. Nat. Genet. 52, 177–186 (2020).

doi: 10.1038/s41588-019-0569-6 pubmed: 32015526

Bylstra, Y. et al. Implementation of genomics in medical practice to deliver precision medicine for an Asian population. NPJ Genom. Med. 4, 12 (2019).

doi: 10.1038/s41525-019-0085-8 pubmed: 31231544 pmcid: 6555782

McGuire, A. L. et al. The road ahead in genetics and genomics. Nat. Rev. Genet. 21, 581–596 (2020).

doi: 10.1038/s41576-020-0272-6 pubmed: 32839576 pmcid: 7444682

Life Insurance Association (LIA) Moratorium on Genetic Testing and Insurance (Singapore Ministry of Health, 2021).

Lysaght, T. et al. Trust and trade-offs in sharing data for precision medicine: a national survey of Singapore. J. Pers. Med. 11, 921 (2021).

Lysaght, T. et al. ‘Who is watching the watchdog?’: ethical perspectives of sharing health-related data for precision medicine in Singapore. BMC Med. Ethics 21, 118 (2020).

doi: 10.1186/s12910-020-00561-8 pubmed: 33213433 pmcid: 7678103

Ong, S., Ling, J., Ballantyne, A., Lysaght, T. & Xafis, V. Perceptions of ‘precision’ and ‘personalised’ medicine in Singapore and associated ethical issues. Asian Bioeth. Rev. 13, 179–194 (2021).

doi: 10.1007/s41649-021-00165-3 pubmed: 33959200 pmcid: 8079483

Majithia, S. et al. Cohort profile: the Singapore Epidemiology of Eye Diseases study (SEED). Int. J. Epidemiol. 50, 41–52 (2021).

doi: 10.1093/ije/dyaa238 pubmed: 33393587

Tan, K. et al. Cohort profile: the Singapore Multi-Ethnic Cohort (MEC) study. Int. J. Epidemiol. 47, 699–699j (2018).

doi: 10.1093/ije/dyy014 pubmed: 29452397

Soh, S. et al. Cohort profile: Growing Up in Singapore Towards healthy Outcomes (GUSTO) birth cohort study. Int. J. Epidemiol. 43, 1401–1409 (2014).

doi: 10.1093/ije/dyt125 pubmed: 23912809

Yap, J. et al. Harnessing technology and molecular analysis to understand the development of cardiovascular diseases in Asia: a prospective cohort study (SingHEART). BMC Cardiovasc. Disord. 19, 259 (2019).

doi: 10.1186/s12872-019-1248-3 pubmed: 31752689 pmcid: 6873552

Van der Auwera G. A. & O'Connor, B. D. Genomics in the Cloud: Using Docker, GATK, and WDL in Terra 1st edn (O’Reilly Media, 2020).

Poplin, R. et al. Scaling accurate genetic variant discovery to tens of thousands of samples. Preprint at bioRxiv https://doi.org/10.1101/201178 (2018).

McLaren, W. et al. The Ensembl Variant Effect Predictor. Genome Biol. 17, 122 (2016).

doi: 10.1186/s13059-016-0974-4 pubmed: 27268795 pmcid: 4893825

Landrum, M. J. et al. ClinVar: improving access to variant interpretations and supporting evidence. Nucleic Acids Res. 46, D1062–D1067 (2018).

Code of Practice for Key Office Holders Under the Healthcare Services Act (Singapore Ministry of Health, 2019).

Doyle, D. L. et al. 2013 review and update of the genetic counseling practice based competencies by a task force of the accreditation council for genetic counseling. J. Genet. Couns. 25, 868–879 (2016).

doi: 10.1007/s10897-016-9984-3 pubmed: 27333894

Christenhusz, G. M., Devriendt, K. & Dierickx, K. To tell or not to tell? A systematic review of ethical reflections on incidental findings arising in genetics contexts. Eur. J. Hum. Genet. 21, 248–255 (2013).

doi: 10.1038/ejhg.2012.130 pubmed: 22739341

Green, R. C. et al. ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genet. Med. 15, 565–574 (2013).

doi: 10.1038/gim.2013.73 pubmed: 23788249 pmcid: 3727274

eMERGE Clinical Annotation Working Group. Frequency of genomic secondary findings among 21,915 eMERGE network participants. Genet. Med. 22, 1470–1477 (2020).

Kuo, C. W. et al. Frequency and spectrum of actionable pathogenic secondary findings in Taiwanese exomes. Mol. Genet. Genomic Med. 8, e1455 (2020).

doi: 10.1002/mgg3.1455 pubmed: 32794656 pmcid: 7549563

Chen, W. et al. Secondary findings in 421 whole exome-sequenced Chinese children. Hum. Genomics 12, 42 (2018).

doi: 10.1186/s40246-018-0174-2 pubmed: 30217213 pmcid: 6137878

Van Hout, C. V. et al. Exome sequencing and characterization of 49,960 individuals in the UK Biobank. Nature 586, 749–756 (2020).

doi: 10.1038/s41586-020-2853-0 pubmed: 33087929 pmcid: 7759458

Cohen, J. T., Goodell, S. & Neumann, P. J. The cost savings and cost-effectiveness of clinical preventive care. In Synthesis Project (Robert Wood Johnson Foundation, 2009).

Hatz, M. H., Schremser, K. & Rogowski, W. H. Is individualized medicine more cost-effective? A systematic review. Pharmacoeconomics 32, 443–455 (2014).

doi: 10.1007/s40273-014-0143-0 pubmed: 24574059

Kasztura, M., Richard, A., Bempong, N. E., Loncar, D. & Flahault, A. Cost-effectiveness of precision medicine: a scoping review. Int. J. Public Health 64, 1261–1271 (2019).

doi: 10.1007/s00038-019-01298-x pubmed: 31650223